Drug intelligence / Profile preview

EGTX004

Development stage: Preclinical
Lead developer: Engitix Therapeutics

Overview

EGTX004 is an investigational therapeutic developed by Engitix for the treatment of solid tumors and advanced fibrosis. It is classified as both an antifibrotic and antineoplastic agent, though its precise mechanism of action has not been disclosed. The drug is being advanced using Engitix’s proprietary extracellular matrix-based discovery platform, which focuses on targeting disease-related mechanisms in fibrotic diseases and tumor stroma. As of the latest updates, EGTX004 remains in early research or discovery stages with no clinical trials reported[1][2][7].

Beyond the preview

Go deeper on EGTX004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGTX004.

Explore the full profile